Pfizer, Inc. · NYSE:PFE

Pfizer — Investor Presentation (November 2026)

29 slides from Pfizer's investor presentation, Nov 12, 2026

  1. Slide 1: Pfizer Pflash: A Spotlight on the Trispecific Antibody Tilrekimig

    Pfizer Pflash: A Spotlight on the Trispecific Antibody Tilrekimig November 12, 2026 Classified – Confidential Presentation intended 1 for the investment community

  2. Slide 2: Forward-Looking Statements and Other Notices

    Forward-Looking Statements and Other Notices Our discussions during this presentation will include forward-looking statements about, among other topics, Pfizer’s investigational inflammation and immunology portfolio, including tilrekimig (PF-07275315), an investigational potential first-in-class tri

  3. Slide 3: Speakers

    Speakers Host Joining for Q&A Francesca DeMartino Mike Vincent Christian Antoni Chief Investor Chief Inflammation & Chief Development Relations Officer Immunology (I&I) Officer Officer, I&I 3

  4. Slide 4: R&D Strategy

    R&D Strategy To Discover and Develop the Next Wave of Breakthroughs That Change Patients’ Lives Inflammation & Internal Oncology Vaccines Immunology Medicine Supported by Expertise Across Three Core Modalities. Transforming with AI. Small Molecules Biologics Vaccines End-to-End AI Inhibitors, Activa

  5. Slide 5: Diverse Inflammation & Immunology Portfolio

    Diverse Inflammation & Immunology Portfolio Select mid-to-late-stage inflammatory programs Phase 2 Phase 3 / Registration5 Approved Targeting LITFULO1 Dazukibart CSU DM and PM Molecular LITFULO1 LITFULO1 Drivers of Hidradenitis Suppurativa Moderate Alopecia Areata 6 Dysfunction to Ompekimig LITFULO1

  6. Slide 6: Diverse Inflammation & Immunology Portfolio

    Diverse Inflammation & Immunology Portfolio Select mid-to-late-stage inflammatory programs Phase 2 Phase 3 / Registration5 Approved Targeting LITFULO1 Dazukibart CSU DM and PM Molecular LITFULO1 LITFULO1 Drivers of Hidradenitis Suppurativa Moderate Alopecia Areata 6 Dysfunction to Ompekimig LITFULO1

  7. Slide 7: Tilrekimig Phase 2 Atopic Dermatitis Data: The Key Takeaways

    Tilrekimig Phase 2 Atopic Dermatitis (AD) Data: The Key Takeaways1 Robust Efficacy Favorable Safety Pipeline-in-a-Product Profile Opportunity Potentially superior to dupilumab2† Lower frequency of conjunctivitis Strong Phase 2 data in AD with ongoing Phase 3 trial and injection site reactions in sup

  8. Slide 8: Tilrekimig is Directed Against Validated & Complementary Targets

    Tilrekimig is Directed Against Validated & Complementary Targets First-in-class approach directly targets IL-4, IL-13, and TSLP ligands for potentially additive effects Tilrekimig Anti-IL-13 IL-4 TSLP Anti-TSLP IL-4 IL-13 Anti-IL-4 Engineered Fc region extends t1/2 to ~37 days1,2 IL-4Rα γC IL-4Rα IL

  9. Slide 9: Tilrekimig is Directed Against Validated & Complementary Targets

    Tilrekimig is Directed Against Validated & Complementary Targets First-in-class approach directly targets IL-4, IL-13, and TSLP ligands for potentially additive effects Tilrekimig Tezepelumab6 Anti-IL-13 IL-4 TSLP Tralokinumab4 Lebrikizumab5 Anti-TSLP IL-4 IL-13 Anti-IL-4 Dupilumab3 Dupilumab3 Engin

  10. Slide 10: Atopic Dermatitis is the Leading Contributor to Skin Disease Burden

    Atopic Dermatitis is the Leading Contributor to Skin Disease Burden1-6 Moderate-to-severe atopic dermatitis affects ~9.8M people in the U.S.7 Many Patients with Moderate-to-Severe Atopic Dermatitis Receiving Advanced Systemic Therapies Do Not Achieve Treatment Targets8 Skin Clearance 82% Missed opti

  11. Slide 11: Tilrekimig Shows Improved In Vitro Functional Potency vs. Dupilumab

    Tilrekimig Shows Improved In Vitro Functional Potency vs. Dupilumab, Supporting its Potential to Deliver Enhanced Efficacy Inhibition of IL-4, IL-13 or TSLP-Stimulated Signaling in a Monocyte CD23 Expression Assay1* ~13x Higher Functional Potency vs. ~7x Higher Functional Potency vs. Comparable Func

  12. Slide 12: Distinct Inflammatory Pathways Driven by IL-4/13 and TSLP

    Distinct Inflammatory Pathways Driven by IL-4/13 and TSLP Suggest Combined Blockade May Drive Additive Efficacy in Atopic Dermatitis Human Skin Heatmap of Gene Expression Changes with IL-4/13 and TSLP Stimulation1 3 Explant Data: IL-4/13 Induced >2-fold Expression Expression Increased IL-4/13 and Ch

  13. Slide 13: Tilrekimig Phase 2 Atopic Dermatitis Data: The Key Takeaways

    Tilrekimig Phase 2 Atopic Dermatitis (AD) Data: The Key Takeaways1 Robust Efficacy Favorable Safety Pipeline-in-a-Product Profile Opportunity Potentially superior to dupilumab2† Lower frequency of conjunctivitis Strong Phase 2 data in AD with ongoing Phase 3 trial and injection site reactions in sup

  14. Slide 14: Phase 2 Trial of Tilrekimig in Atopic Dermatitis

    Phase 2 Trial of Tilrekimig in Atopic Dermatitis1 Stage 1 Stage 2 Stage 3 Tilrekimig 450 mg Q2W2 in Tilrekimig dose ranging in Tilrekimig in biologic- biologic-naïve participants3 biologic-naïve participants3 experienced population3 Today’s Focus is Stage 2: Dose-Ranging Study with 16-Week Treatment

  15. Slide 15: Demonstrated Robust Efficacy on Primary Endpoint in Phase 2

    Tilrekimig Demonstrated Robust Efficacy on Primary Endpoint in Ph 2 Percentage of Tilrekimig Participants Achieving a ≥75% Improvement in Atopic Dermatitis Disease Score (EASI-75) Increased Over Time with Significant Improvements for All Doses vs. Placebo at Week 16* 80 Met Primary Endpoint (Week 16

  16. Slide 16: Phase 2 Primary Endpoint Data Support Potential to Demonstrate Superior Efficacy vs. Dupilumab

    Phase 2 Primary Endpoint Data Support Potential to Demonstrate Superior Efficacy vs. Dupilumab in Ongoing Phase 3 Trial Placebo-Adjusted % with ≥75% Improvement in EASI (EASI-75) at Week 16 Cross-Trial 51.9 49.4 Comparison: Tilrekimig Phase 2 Trial1 vs. 36.6 32.3 Pivotal Trials of Dupilumab (SOLO-1

  17. Slide 17: Tilrekimig Skin Clearance Similar to SOC Benchmarks at Week 16

    Tilrekimig Skin Clearance Similar to SOC Benchmarks at Week 16 Anticipate tilrekimig skin clearance scores to improve and potentially differentiate from SOC with continued dosing Placebo-Adjusted % with IGA 0/1 and ≥2-point Improvement from Baseline at Week 16 Cross-Trial IGA vIGA-AD Comparison: Til

  18. Slide 18: Tilrekimig: Improved Itch Relief Relative to SOC Benchmark at Week 16

    Tilrekimig: Improved Itch Relief Relative to SOC Benchmark at Week 16 Itch is the most prevalent and burdensome symptom of atopic dermatitis and the main reason for HCP visits1,2 Placebo-Adjusted % with ≥4-point Improvement in Itch Score5 at Week 16 Cross-Trial Comparison: Tilrekimig 43.6 35.3 Phase

  19. Slide 19: Biomarker Data Support Tilrekimig's Potential Efficacy & Differentiation

    Biomarker Data Support Tilrekimig’s Potential Efficacy & Differentiation Observed significant reductions across key type 2 inflammatory markers, consistent with tilrekimig’s MOA Significant Reductions in TARC at Week 16 in Significant Reductions in Blood Eosinophils at Week 16 200 mg and 400 mg Dose

  20. Slide 20: Tilrekimig Phase 2 Atopic Dermatitis Data: The Key Takeaways

    Tilrekimig Phase 2 Atopic Dermatitis (AD) Data: The Key Takeaways1 Robust Efficacy Favorable Safety Pipeline-in-a-Product Profile Opportunity Potentially superior to dupilumab2† Lower frequency of conjunctivitis Strong Phase 2 data in AD with ongoing Phase 3 trial and injection site reactions in sup

  21. Slide 21: Tilrekimig was Well-tolerated with a Favorable Safety Profile in Phase 2

    Tilrekimig was Well-tolerated with a Favorable Safety Profile in Phase 2* No dose-dependent safety signals or serious adverse events related to tilrekimig1 Comparable Numerically lower No eosinophilia Similar rates of TEAE rates injection site reaction AEs in tilrekimig or conjunctivitis between til

  22. Slide 22: Two Phase 3 Trials of Tilrekimig in Atopic Dermatitis Ongoing

    Two Phase 3 Trials of Tilrekimig in Atopic Dermatitis Ongoing Tilrekimig vs. Placebo and vs. Dupilumab1 Initial Treatment (24 weeks) Maintenance Period (28 weeks) Tilrekimig Designed to evaluate N ≈ 1375 (2:2:1) maintenance, extended dosing Adults and Adolescents with Moderate-to- R Dupilumab interv

  23. Slide 23: Tilrekimig Phase 2 Atopic Dermatitis Data: The Key Takeaways

    Tilrekimig Phase 2 Atopic Dermatitis (AD) Data: The Key Takeaways1 Robust Efficacy Favorable Safety Pipeline-in-a-Product Profile Opportunity Potentially superior to dupilumab2† Lower frequency of conjunctivitis Strong Phase 2 data in AD with ongoing Phase 3 trial and injection site reactions in sup

  24. Slide 24: Tilrekimig Embodies Go-Forward I&I Research & Development Strategy

    Tilrekimig Embodies Go-Forward I&I Research & Development Strategy Enabled by capabilities and expertise in small molecules, multispecific antibodies and systems immunology Identify Demonstrate Strategically Biological Axis Clinical POC Expand That drives multiple diseases In high-value anchor To ad

  25. Slide 25: IL-4, IL-13 and TSLP are Key Drivers of Airway Inflammation

    IL-4, IL-13 and TSLP are Key Drivers of Airway Inflammation TSLP IL-4 IL-13 Upstream epithelial alarmin Programs the type 2 immune response Drives effects within the airway Released by the airway lining in Helps establish and amplify type 2 Drives mucus production5,6 response to environmental trigge

  26. Slide 26: IL-4/13 & TSLP Pathways are Validated Targets in Airway Diseases

    IL-4/13 & TSLP Pathways are Validated Targets in Airway Diseases Approved antibodies target IL-4/13 & TSLP pathways in airway diseases, yet substantial unmet need persists1-3 Asthma COPD IL-4/13 Signaling is a Validated Target in IL-4/13 Signaling is a Validated Target in COPD Type 2-High Asthma4 wi

  27. Slide 27: Tilrekimig's Potential First Wave: Atopic Dermatitis, Asthma and COPD

    Tilrekimig’s Potential First Wave: Atopic Dermatitis, Asthma and COPD* Select Late-Stage Trials* Differentiation Goal in Phase 3 Phase 3 Tilrekimig vs. Placebo and vs. Dupilumab1 Aim to Differentiate with Atopic Dermatitis Superior Efficacy vs. Dupilumab Tilrekimig + Topical Medicine vs. Placebo + T

  28. Slide 28: Phase 2 Data Support Tilrekimig's Potential to be a First-in-Class Trispecific

    Ph 2 Data Support Tilrekimig’s Potential to be a First-in-Class Trispecific and Leading Biologic Therapy for Type 2 Inflammatory Disorders Robust Efficacy1 Favorable Safety Pipeline-in-a-Product Profile1 Opportunity Lower frequency of conjunctivitis Potentially superior to dupilumab2† Strong Phase 2

  29. Slide 29: Q&A

    Q&A Host Francesca DeMartino Mike Vincent Christian Antoni Chief Investor Chief Inflammation & Chief Development Relations Officer Immunology (I&I) Officer Officer, I&I 29

Pfizer — Investor Presentation (November 2026) on 6ix